Development of Bio-Rad's PrimePCR qPCR assay portfolio

Bio-Rad Laboratories, California, USA

Biogazelle developed the most comprehensive portfolio of validated Research Use Only (RUO) qPCR assays for human, mouse and rat. The assays are commercialized by Bio-Rad under the PrimePCR brand. Assay development was performed using our primerXL pipeline incorporating state-of-the-art in silico assay validation. All qPCR assays were wet lab validated (including deep amplicon sequencing to confirm specificity) and come with a validation report.

Development of a non-invasive diagnostic microRNA test for endometriosis

dr. Arne Vanhie, Department of Obstetrics and Gynaecology, KULeuven, Belgium

Endometriosis is an estrogen-dependent disease that results in pelvic pain and infertility. It is histologically characterized by the displacement of endometrial tissue to extrauterine locations. Laparoscopy remains the gold standard for the diagnosis of the condition. However, the invasive nature of surgery, coupled with the lack of a laboratory biomarker for the disease, results in a mean latency of 7-11 years from onset of symptoms to definitive diagnosis. Unfortunately, this delay in diagnosis may have significant consequences in terms of disease progression.

Evaluation of candidate-biomarkers predictive of therapy response or resistance using digital PCR on plasma-derived cell-free DNA

dr. Brian Lockhart, Servier, France

Servier is a French pharmaceutical group and key-player in oncology. For their LONSURF pipeline, they have initiated a phase I dose escalation study with the exploratory objective to evaluate biomarkers that may predict response and resistance to LONSURF in combination therapy. To this end, Biogazelle used digital PCR to quantify cancer gene mutations in patient plasma samples.

Identification of small non-coding RNAs in renal cell carcinoma using small RNA sequencing

prof. Jörg Ellinger, Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn, Germany

Renal cell carcinoma (RCC) is the most frequent renal malignancy. Current modalities do not allow precise discrimination of malignant tumors. To date, no biomarker is available for clinical practice, making an accurate and non-invasive identification of RCC impossible. To this end, Biogazelle performed small RNA sequencing to determine the expression of small RNAs in RCC.